| abstract |
The present invention discloses recombinant human erythropoietin (rhEPO)-Fc fusion protein produced by using a genetic engineering method, polyribonucleotide for encoding the fusion protein and a method for preparing and purifying the fusion protein, wherein the fusion protein is composed of human erythropoietin and the Fc fragment of human IgG2. The fusion protein can be effectively expressed in mammalian cells. The fusion protein has a simple purification process and is favorable for further large-scale preparation. Compared with natural EPO, the rhEPO-Fc fusion protein obtained by the present invention has the characteristic of long serum half life. Meanwhile, the bioactivity of the fusion protein, which is similar to the natural EPO, is still kept on the basis of the same molecule number. The fusion protein can be used for treating anemia caused by various reasons, such as anemia caused by chronic renal failure, induction anemia after the AZT treatment of AIDS patients, anemia caused by tumor, anemia caused by tumor chemotherapy, prematurity anemia, anemia caused by rheumatoid arthritis, etc. |